News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
ANTENGENE-B (06996.HK) ATG-022 Approved in Mainland to Initiate Pivotal Study
ANTENGENE-B (06996.HK) announced that, following review by the Center for Drug Evaluation of the National Medical Products Administration, the company has received approval from th...
Reset
Send
The window will close in 5 seconds
ANTENGENE-B (06996.HK) ATG-022 Approved in Mainland to Initiate Pivotal Study
Close
Recommend
3
Positive
4
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

ANTENGENE-B (06996.HK)  +0.320 (+7.748%)    Short selling $1.42M; Ratio 13.275%   announced that, following review by the Center for Drug Evaluation of the National Medical Products Administration, the company has received approval from the Center for Drug Evaluation to initiate a pivotal Phase III CLINCH-3 study of ATG-022, an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), for the treatment of CLDN18.2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study is expected to be first launched in China and is planned to be conducted as a multi-regional clinical trial (MRCT). (jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.